Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:59:05 ON 12 MAY 2008

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:59:15 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAY 2008  HIGHEST RN 1020256-26-1
DICTIONARY FILE UPDATES:  11 MAY 2008  HIGHEST RN 1020256-26-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10549972\10549972b.str
```



```
chain nodes :
7
ring nodes :
1  2  3  4  5  6  8  9  10  11  12  13  14  15  16  17  18
chain bonds :
3-8  5-14  6-7
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-13  9-10  10-11  11-12  12-13  14-15  14-18
15-16  16-17  17-18
exact/norm bonds :
6-7  14-15  14-18  15-16  16-17  17-18
exact bonds :
```

3-8 5-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
isolated ring systems :
containing 8 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:59:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   80 TO ITERATE

100.0% PROCESSED   80 ITERATIONS   7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 1064 TO   2136
PROJECTED ANSWERS: 7 TO   298

L2   7 SEA SSS SAM L1

=> d scan

L2   7 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   Benzamide, N-[2-[3-amino-6-[4-[2-(diethylamino)ethoxy]phenyl]-2-pyrazinyl]-
     1H-benzimidazol-6-yl]-3-fluoro-
MF   C30 H30 F N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full
FULL SEARCH INITIATED 09:59:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1456 TO ITERATE

100.0% PROCESSED 1456 ITERATIONS 80 ANSWERS
SEARCH TIME: 00.00.01

L3 80 SEA SSS FUL L1

=> d scan

L3 80 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Pyrazinamine, 3-(1H-benzimidazol-2-yl)-5-(4-fluorophenyl)-
MF C17 H12 F N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	178.82	179.03

FILE 'CAPLUS' ENTERED AT 10:00:10 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 May 2008 VOL 148 ISS 20
FILE LAST UPDATED: 11 May 2008 (20080511/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 4 L3

=> d l4 1-4 ibib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:410663 CAPLUS
DOCUMENT NUMBER: 148:403249
TITLE: Preparation of pyrazine derivatives as Aurora kinase A and/or B inhibitors
INVENTOR(S): Walmsley, Lee David; Drysdale, Martin James; Chen, Ijen
PATENT ASSIGNEE(S): Vernalis (R & D) Limited, UK
SOURCE: PCT Int. Appl., 55pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008038010	A1	20080403	WO 2007-GB3687	20070928

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-19342 A 20060930

GI



I



II

AB Title compds. represented by the formula I [wherein R1-R5 = independently H, OH, alkyl, etc.; R = H or alkyl; A, B = H or -Z-Ar; Z = -C(=O)-NH-, -NH-C(=O)-, -C(=O)-N(-CH3)- or -N(-CH3)-C(=O)-; Ar = (un)substituted (hetero)aryl; and pharmaceutically acceptable salts, hydrates or solvates thereof] were prepared as inhibitors of Aurora kinase A and/or B. For example, II was provided in a multi-step synthesis starting from the reaction of Me 3-amino-6-bromopyrazine-2-carboxylate with 3-(hydroxymethyl)benzoic acid. I were tested for cellular responses to Aurora inhibition and flow cytometry assay. Thus, I and their pharmaceutical compns. are useful as inhibitors of Aurora kinase A and/or B for the treatment of the condition responsive to inhibition of Aurora Kinase activity is a hyperproliferative disease such as cancer.

IT 1015728-79-6P, 2-[3-Amino-6-[3-[(3-hydroxymethylpiperidin-1-yl)methyl]phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide 1015728-87-6P, 2-[3-Amino-6-[3-[[ethyl(2-hydroxyethyl)amino]methyl]phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide 1015728-95-6P, 2-[3-Amino-6-[3-[(piperidin-1-yl)methyl]phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide 1015729-34-6P, 2-[3-Amino-6-[3-[2-[ethyl(2-hydroxyethyl)amino]ethyl]phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide 1015729-42-6P, 2-[3-Amino-6-[3-[2-(4-hydroxymethylpiperidin-1-yl)ethyl]phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide 1015729-50-6P, 2-[3-Amino-6-[3-[2-(3-hydroxymethylpiperidin-1-yl)ethyl]phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide 1015729-58-4P 1015729-66-4P 1015729-73-3P 1015729-81-3P 1015729-89-1P 1015729-97-1P 1015730-05-8P 1015730-21-8P 1015730-28-5P 1015730-35-4P 1015730-43-4P 1015730-50-3P 1015730-57-0P 1015730-65-0P 1015730-81-0P 1015730-89-8P 1015730-97-8P 1015731-05-1P 1015731-13-1P 1015731-20-0P 1015731-27-7P 1015731-35-7P 1015731-43-7P

1015731-51-7P 1015731-59-5P 1015731-66-4P
1015731-73-3P 1015731-81-3P 1015731-89-1P
1015731-97-1P 1015732-03-2P 1015732-10-1P
1015732-18-9P 1015732-26-9P 1015732-33-8P
1015732-41-8P 1015732-49-6P 1015732-57-6P
1015732-65-6P 1015732-73-6P 1015732-80-5P
1015732-87-2P 1015732-95-2P 1015733-03-5P
1015733-10-4P 1015733-18-2P 1015733-26-2P
1015733-34-2P 1015733-42-2P 1015733-57-9P
1015750-03-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazine derivs. as Aurora kinase A and/or B inhibitors)

RN 1015728-79-6 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-[3-[[3-(hydroxymethyl)-1-piperidinyl]methyl]phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015728-87-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015728-95-6 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-[3-(1-piperidinylmethyl)phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015729-34-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015729-42-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015729-50-6 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-[3-[2-[3-(hydroxymethyl)-1-piperidinyl]ethyl]phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015729-58-4 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[3-(hydroxymethyl)phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3,5-difluoro- (CA INDEX NAME)



RN 1015729-66-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015729-73-3 CAPLUS
CN Benzamide, N-[2-[3-amino-6-(4-hydroxyphenyl)-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro- (CA INDEX NAME)



RN 1015729-81-3 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[3-[2-(diethylamino)ethoxy]phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro- (CA INDEX NAME)



RN 1015729-89-1 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[4-[2-(diethylamino)ethoxy]phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro- (CA INDEX NAME)



RN 1015729-97-1 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[4-(2-hydroxyethyl)phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro- (CA INDEX NAME)



RN 1015730-05-8 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[3-[2-(4-morpholinyl)ethyl]phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro- (CA INDEX NAME)



RN 1015730-21-8 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-(3-amino-6-phenyl-2-pyrazinyl)-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015730-28-5 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[3-[2-(4-morpholinyl)ethyl]phenyl]-2-pyrazinyl]-1-methyl-1H-benzimidazol-5-yl]-3-fluoro- (CA INDEX NAME)



RN 1015730-35-4 CAPLUS
CN Benzenepropanoic acid, 3-[5-amino-6-[6-[(3-fluorobenzoyl)amino]-1H-benzimidazol-2-yl]-2-pyrazinyl]- (CA INDEX NAME)



RN 1015730-43-4 CAPLUS
CN Benzeneacetic acid, 3-[5-amino-6-[6-[(3-fluorobenzoyl)amino]-1H-benzimidazol-2-yl]-2-pyrazinyl]- (CA INDEX NAME)



RN 1015730-50-3 CAPLUS
CN Benzoic acid, 3-[5-amino-6-[6-[(3-fluorobenzoyl)amino]-1H-benzimidazol-2-yl]-2-pyrazinyl]- (CA INDEX NAME)



RN 1015730-57-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015730-65-0 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[3-(2-hydroxyethoxy)phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro- (CA INDEX NAME)



RN 1015730-81-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[3-amino-6-[3-(2-hydroxyethyl)phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)-1-methyl- (CA INDEX NAME)



RN 1015730-89-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015730-97-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-05-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-13-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-20-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-27-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[3-amino-6-[3-[3-[4-(hydroxymethyl)-1-piperidinyl]propyl]phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)-1-methyl- (CA INDEX NAME)



RN 1015731-35-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-43-7 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-[3-[3-[4-(hydroxymethyl)-1-piperidinyl]propyl]phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015731-51-7 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[3-[3-[4-(hydroxymethyl)-1-piperidinyl]propyl]phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro-N-methyl- (CA INDEX NAME)



RN 1015731-59-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-66-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-73-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-81-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-89-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015731-97-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-03-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-10-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-18-9 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-(3-hydroxyphenyl)-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015732-26-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-33-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-41-8 CAPLUS
CN Benzamide, N-[2-[3-amino-6-(3-hydroxyphenyl)-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro- (CA INDEX NAME)



RN 1015732-49-6 CAPLUS
CN Benzamide, N-[2-[3-amino-6-(4-hydroxyphenyl)-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro-N-methyl- (CA INDEX NAME)



RN 1015732-57-6 CAPLUS
CN Benzoic acid, 4-[5-amino-6-[6-[(3-fluorobenzoyl)amino]-1H-benzimidazol-2-yl]-2-pyrazinyl]- (CA INDEX NAME)



RN 1015732-65-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-73-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-80-5 CAPLUS
CN Benzamide, N-[2-[3-amino-6-[4-(hydroxymethyl)phenyl]-2-pyrazinyl]-1H-benzimidazol-6-yl]-3-fluoro-N-methyl- (CA INDEX NAME)



RN 1015732-87-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015732-95-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015733-03-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015733-10-4 CAPLUS
CN Benzamide, N-[2-[3-amino-6-(4-hydroxyphenyl)-2-pyrazinyl]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 1015733-18-2 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-(4-hydroxyphenyl)-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015733-26-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1015733-34-2 CAPLUS
CN Benzamide, N-[2-[3-amino-6-(4-hydroxyphenyl)-2-pyrazinyl]-1-methyl-1H-

benzimidazol-5-yl]-3-fluoro- (CA INDEX NAME)



RN 1015733-42-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A

RN 1015733-57-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1015750-03-4 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-[3-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



IT 1015728-71-8P, 2-[3-Amino-6-(3-formylphenyl)pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide
1015729-18-6P, 2-[3-Amino-6-[3-(2-hydroxyethyl)phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide
1015729-26-6P, 2-[3-Amino-6-[3-(2-oxoethyl)phenyl]pyrazin-2-yl]-1H-benzimidazole-5-carboxylic acid N-(3-fluorophenyl)amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazine derivs. as Aurora kinase A and/or B inhibitors)
RN 1015728-71-8 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-(3-formylphenyl)-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015729-18-6 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-[3-(2-hydroxyethyl)phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 1015729-26-6 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[3-amino-6-[3-(2-oxoethyl)phenyl]-2-pyrazinyl]-N-(3-fluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:558540 CAPLUS
DOCUMENT NUMBER: 145:62865
TITLE: Preparation of 1H-pyrrolo[2,3-b]pyridines as inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK-1)
INVENTOR(S): Frazee, James S.; Hammond, Marlys; Kano, Kazuya; Manns, Sharada; Nakamura, Hiroko; Thompson, Scott Kevin; Washburn, David G.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063167	A1	20060615	WO 2005-US44485	20051208

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
EP 1828180 A1 20070905 EP 2005-853413 20051208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
PRIORITY APPLN. INFO.: US 2004-634149P P 20041208
WO 2005-US44485 W 20051208
OTHER SOURCE(S): MARPAT 145:62865
GI



AB Title compds. I [wherein Ra, Rb = (un)substituted Ph, pyridinyl, thiophenyl, etc.] and pharmaceutically acceptable salts or solvates thereof were prepared as SGK-1 kinase inhibitors. For instance, successive coupling reaction of 5-bromo-1H-pyrrolo[2,3-b]pyridine with phenylboronic acid (99%), bromination in the 3-position of the pyrrolopyridine ring with Br2, N-protection with TsCl (68% for two steps), coupling with 4-carboxyphenylboronic acid, and deprotection with NaOH (60%) gave benzoic acid II. I were found to have SGK-1 inhibitory activity with IC50 values of below 1.5 μM in a FR assay. Therefore, I and their pharmaceutical compns. are useful for the treatment of diseases mediated by SGK-1, such as renal and cardiovascular disease.

IT 890843-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of rhodamine-containing glycinamide as substrate in the enzymic assay of pyrrolopyridines as inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK-1))

RN 890843-32-0 CAPLUS

CN Acetamide, 2-[[3-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]phenyl]amino]- (CA INDEX NAME)



IT 890843-34-2P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(substrate; preparation of rhodamine-containing glycinamide as substrate in the
enzymic assay of pyrrolopyridines as inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK-1))
RN 890843-34-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-carboxamide, 3',6'-diamino-N-[2-[[3-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]phenyl]amino]-2-oxoethyl]-3-oxo- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:817641 CAPLUS
DOCUMENT NUMBER: 141:332217
TITLE: Preparation of aminopyrazine derivatives as ROCK kinase inhibitors
INVENTOR(S): Alberti, Michael John; Drewry, David Harold; Miller, David Drysdale; Bamborough, Paul
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004084813	A2	20041007	WO 2004-US8301	20040318
WO 2004084813	A3	20050217		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1606266	A2	20051221	EP 2004-757813	20040318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006520794	T	20060914	JP 2006-507319	20040318
US 20060084651	A1	20060420	US 2005-549972	20050920
PRIORITY APPLN. INFO.:			US 2003-456872P	P 20030321
			WO 2004-US8301	W 20040318

OTHER SOURCE(S): MARPAT 141:332217

GI



I

AB The title compds. [I; A = (hetero)aryl, alkenyl, CN, etc.; D = (un)substituted benzimidazolyl, imidazopyridynyl, etc.], useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity, were prepared E.g., two alternate methods of preparing 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine, were given. All 26 exemplified compds. I showed inhibitory activity vs. Rock-1 with pIC50 of 5.0 or greater.

IT 769967-87-5P, 3-(1-Ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-phenylpyrazin-2-amine 769967-88-6P, 3-(1-Ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)pyrazin-2-amine 769967-89-7P, 3-(1-Ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine 769967-91-1P, 5-(4-Aminophenyl)-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine 769967-95-5P, 3-(1H-Benzimidazol-2-yl)-5-(3-fluorophenyl)pyrazin-2-amine 769967-96-6P, 3-(1H-Benzimidazol-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine 769967-97-7P, 4-[5-Amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]-N,N-dimethylbenzenesulfonamide 769967-98-8P, 3-(1-Ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-[3-(methylsulfonyl)phenyl]pyrazin-2-amine 769967-99-9P, 3-[4-[5-Amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl]propanoic acid 769968-00-5P, [4-[5-Amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy]acetic acid 769968-01-6P, [3-[5-Amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy]acetic acid 769968-02-7P 769968-03-8P, Benzyl 4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoate 769968-04-9P,

5-[4-(Benzyloxy)phenyl]-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine 769968-05-0P, 5-[1,1'-Biphenyl-3-yl)-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine 769968-06-1P 769968-07-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyrazine derivs. as ROCK kinase inhibitors)

RN 769967-87-5 CAPLUS
CN 2-Pyrazinamine, 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-phenyl- (CA INDEX NAME)



RN 769967-88-6 CAPLUS
CN 2-Pyrazinamine, 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 769967-89-7 CAPLUS
CN 2-Pyrazinamine, 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 769967-91-1 CAPLUS

CN 2-Pyrazinamine, 5-(4-aminophenyl)-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 769967-95-5 CAPLUS
CN 2-Pyrazinamine, 3-(1H-benzimidazol-2-yl)-5-(3-fluorophenyl)- (CA INDEX NAME)



RN 769967-96-6 CAPLUS
CN 2-Pyrazinamine, 3-(1H-benzimidazol-2-yl)-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 769967-97-7 CAPLUS
CN Benzenesulfonamide, 4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 769967-98-8 CAPLUS
CN 2-Pyrazinamine, 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 769967-99-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]- (CA INDEX NAME)



RN 769968-00-5 CAPLUS
CN Acetic acid, 2-[4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]phenoxy]- (CA INDEX NAME)



RN 769968-01-6 CAPLUS
CN Acetic acid, 2-[3-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]phenoxy]- (CA INDEX NAME)



RN 769968-02-7 CAPLUS
CN Methanesulfonamide, N-[4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]phenyl]- (CA INDEX NAME)



RN 769968-03-8 CAPLUS
CN Benzoic acid, 4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]-, phenylmethyl ester (CA INDEX NAME)



RN 769968-04-9 CAPLUS
CN 2-Pyrazinamine, 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 769968-05-0 CAPLUS
CN 2-Pyrazinamine, 5-[1,1'-biphenyl]-3-yl-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 769968-06-1 CAPLUS
CN Benzoic acid, 4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-2-pyrazinyl]- (CA INDEX NAME)



RN 769968-07-2 CAPLUS
CN Carbamic acid, [[3-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazinyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:633705 CAPLUS
DOCUMENT NUMBER: 139:180070
TITLE: Preparation of 2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazoles as inhibitors of GSK-3
INVENTOR(S): Harbeson, Scott L.; Arnost, Michael J.; Green, Jeremy; Savic, Vladimir
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066629	A2	20030814	WO 2003-US3655	20030206
WO 2003066629	A3	20031030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2475633	A1	20030814	CA 2003-2475633		20030206
AU 2003215087	A1	20030902	AU 2003-215087		20030206
US 20040034037	A1	20040219	US 2003-360535		20030206
EP 1472245	A2	20041103	EP 2003-710903		20030206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005526028	T	20050902	JP 2003-566002		20030206
MX 2004PA07697	A	20041110	MX 2004-PA7697		20040806
NO 2004003726	A	20041108	NO 2004-3726		20040906
US 20070270420	A1	20071122	US 2007-776756		20070712
PRIORITY APPLN. INFO.:			US 2002-354843P	P	20020206
			US 2003-360535	A1	20030206
			WO 2003-US3655	W	20030206

OTHER SOURCE(S): MARPAT 139:180070

GI



I



II

AB The title compds. [I; ring A = (un)substituted 5-7 membered (un)saturated ring having 0-3 heteroatoms, and wherein ring A is optionally fused to 5-8 membered ring having 0-3 heteroatoms; ring B = (un)substituted 5-6 membered ring having 0-4 heteroatoms; W = N, CR4; X = N, CH (wherein at least one of W and X = N); R3 = TCN, LR; T = a bond, alkylidene; L = a bond, alkylidene wherein up to two methylene units of L are replaced by O, S, CO, etc.; R4 = LR, halo, TNO2, TCN; R = H, alkyl, aryl, etc.], useful as inhibitors of GSK-3 and Lck protein kinases (biol. data given) for treating and preventing various disorders, such as diabetes, Alzheimer's disease, and transplant rejection, were prepared Thus, reacting 1,2-phenylenediamine with Me 4-aminofurazan-3-carboximidate in the presence of AcOH in MeOH afforded 76% II. A pharmaceutical composition comprising the title compound I, was claimed.

IT 581081-40-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazoles as inhibitors of GSK-3)

RN 581081-40-5 CAPLUS

CN Pyrazinamine, 5-(3-methoxyphenyl)-3-[1-(2-methylpropyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.56	206.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 10:07:20 ON 12 MAY 2008